Gain insights into T-cell expansion, viral vector production and scaling production of mesenchymal stem cells (MSCs) through the use of a functionally closed, automated, cell culture process.

Dr. Beltzer (Terumo BCT, CO, U.S.) will present a number of case studies to describe how process development and economic goals were achieved in both industry and academic settings. Results include up to a 500-fold expansion of T-cells in 12 days, 40 percent reduction in cost of goods (COGs) of growing cells for an allogeneic therapy, and automated viral vector production with titers similar to flask-based processes. Particular attention will be directed toward the process changes often needed to meet these goals.